Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIO-TB: Optimal Treatment Duration for Bacteriologically Unconfirmed TB
NCT07163143Phase 3Recruiting
- Sponsor
- University College London
- Start
- Oct 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of isoniazid, rifampicin, pyrazinamide and ethambutol in Tuberculosis (TB) (6 arms), sponsored by University College London. Primary endpoint: Proportion of participants with an unfavourable TB outcome at 78 weeks. Started Oct 2026; status: recruiting.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07163143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07163143.